Cargando…
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
Down syndrome (DS) is one of the leading causes of intellectual disability, and patients with DS face various health issues, including learning and memory deficits, congenital heart disease, Alzheimer’s disease (AD), leukemia, and cancer, leading to huge medical and social costs. Remarkable advances...
Autores principales: | Duchon, Arnaud, Herault, Yann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891327/ https://www.ncbi.nlm.nih.gov/pubmed/27375444 http://dx.doi.org/10.3389/fnbeh.2016.00104 |
Ejemplares similares
-
Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
por: Atas-Ozcan, Helin, et al.
Publicado: (2021) -
Dosage of the Abcg1-U2af1 Region Modifies Locomotor and Cognitive Deficits Observed in the Tc1 Mouse Model of Down Syndrome
por: Marechal, Damien, et al.
Publicado: (2015) -
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A
por: Nguyen, Thu Lan, et al.
Publicado: (2018) -
DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase
por: Noll, Christophe, et al.
Publicado: (2009) -
Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome
por: Brault, Véronique, et al.
Publicado: (2021)